Staff Writer
Shares of Inspire Pharmaceuticals Inc. fell 58.7 percent Monday after the firm said cystic fibrosis drug denufosol failed to meet its primary and secondary endpoints in a Phase III trial.
The setback was "both disappointing and unexpected," Inspire President and CEO Adrian Adams said during a conference call u particularly because a previous, similarly designed Phase III trial had succeeded.
The first trial u dubbed TIGER-1 u met its primary endpoint of improved forced expiratory volume in one second (FEV1), with a 45 mL difference between the denufosol-treated group and the placebo group after 24 weeks (p = 0.047). FEV1 continued to improve in a 24-week extension study. …
No comments:
Post a Comment